26 January 2023 
EMA/CHMP/26443/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Trulicity 
dulaglutide 
On 26 January 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Trulicity. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted an extension to the existing indication to include children from 10 years of age. For 
information, the full indication will be as follows:2 
Type 2 Diabetes Mellitus 
Trulicity is indicated for the treatment of adults patients 10 years and above with 
insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise 
• 
as monotherapy when metformin is considered inappropriate due to intolerance or 
contraindications 
• 
in addition to other medicinal products for the treatment of diabetes.  
For study results with respect to combinations, effects on glycaemic control and cardiovascular 
events, and the populations studied, see sections 4.4, 4.5 and 5.1. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
